Patient Advocacy in Prior Authorization: What Providers Can Do Better

Imagine being told you need a medication. Your doctor explained why. You agreed. You left the appointment expecting that things were moving forward.

Then nothing happens for two weeks.

You call the pharmacy and they say there's a prior authorization pending. You call your doctor's office and wait on hold. Nobody seems to know exactly when this will be resolved. Your symptoms are getting worse. You're anxious. You're frustrated. And you have no idea what, if anything, you can do.

That's the patient experience of prior authorization — and most providers underestimate how disorienting it is. PA is a workflow problem for clinicians. For patients, it's a crisis of trust.

The Provider's Role Has Changed

A prior authorization isn't just paperwork anymore. It's an advocacy moment.

When a payer's automated system demands justification for a biologic that took you years of training and clinical experience to determine was the right choice, your response to that demand directly affects your patient's outcome. Slow documentation means slow approval. Incomplete documentation means denial. Every day of delay is a day of disease that didn't have to happen.

Most providers think of advocacy as the dramatic moments — the phone call where you argue down a medical director, the letter that gets the denied claim overturned. Those matter. But the more consistent form of advocacy is quieter: submitting complete, thorough documentation the first time, managing the patient's expectations honestly, and tracking the request until it resolves.

The AMA's 2024 survey found that 93% of physicians reported PA caused care delays. The practices that minimize those delays for their patients treat the documentation process as an advocacy act — not an administrative chore.

Step One: Be Honest About the Timeline

Patients who understand what they're about to experience are significantly more likely to stay engaged in the process.

Tell them directly: this drug requires prior authorization. That means the insurance company has to review the request before approving it. Standard reviews take 3 to 7 business days. If there's a denial and appeal, add another 2 to 4 weeks. If you have a complex payer relationship, it could be longer.

That conversation is uncomfortable. It also prevents the patient from assuming silence means failure. Patients who know what to expect call less, panic less, and are far less likely to abandon the treatment out of confusion.

Set up a specific point of contact in your office — one person the patient can reach with questions about their PA status. Ambiguity breeds anxiety. A name and a phone number are advocacy.

Step Two: Make the First Submission Count

This is the highest-leverage advocacy intervention available to any provider.

Most PA denials — estimates range from 60% to 75% across specialty drug categories — are overturned on appeal. That number should be alarming. It means the clinical case was almost always correct. The documentation just failed to make the case on first submission.

Every element of payer-specific criteria that's left unaddressed in the initial request creates a reason to deny. For a biologic in rheumatology, that means documenting disease activity scores, prior DMARD history with specific doses and durations, laboratory values with clinical context, comorbidities, and contraindications to alternatives. Miss one and the automated review flags it.

Payer criteria aren't secret. They publish their clinical coverage policies — usually as Local Coverage Determinations or medical policy documents. Knowing those documents, or using tools that incorporate them, is advocacy. The patient's advocate isn't just the person who argues after a denial. It's the person who builds an airtight case before one happens.

Purpose-built documentation tools reduce the time required to produce that kind of thorough, payer-aligned submission from 45-60 minutes to under 2 minutes. Faster documentation enables same-day submission. Same-day submission compresses the approval timeline. That compression is measurable advocacy.

Step Three: Know When and How to Appeal

Appeals aren't just paperwork retry. A well-constructed appeal is a different kind of document — one that specifically addresses the reason for denial and adds clinical information the initial submission lacked.

When a denial letter arrives, read it carefully. Payers are required to provide a specific reason for denial. That reason tells you exactly what the appeal needs to address. A denial for "failure to document adequate prior treatment" is different from a denial for "does not meet step therapy criteria" — and the appeal that wins one won't necessarily win the other.

The appeal process for most commercial payers follows a predictable path: first-level written appeal, second-level appeal, external independent review. Know the timeline requirements at each stage. Missing an appeal deadline forfeits the right to escalate.

CMS has published appeals process guides for Medicare. For commercial payers, the denial letter itself should include information about appeal rights and deadlines.

Step Four: Request Peer-to-Peer Reviews Without Hesitation

The peer-to-peer review is among the most underused tools in a provider's PA arsenal.

When a biologic is denied, you have the right to speak directly with the physician reviewer who made that determination. Many providers don't know this, or know it and don't pursue it, because it takes time. Requesting and completing a peer-to-peer typically takes 20 to 30 minutes. The reversal rate after peer-to-peer reviews is substantial — some estimates put it above 70% for appropriate specialty drug requests.

Call your plan's provider services line. Request a peer-to-peer for the specific claim. Come prepared with the specific clinical rationale: why the guideline therapies aren't appropriate for this patient, what the disease activity data shows, why this drug is the right intervention. A medical director talking to a treating physician — physician to physician — is a fundamentally different conversation than a form review.

Don't wait until after the first appeal fails. Peer-to-peer can often be requested in parallel with or immediately after initial denial.

Involving Patient Advocacy Organizations

You don't have to fight these battles alone — and neither does your patient.

For oncology patients, organizations like the National Coalition for Cancer Survivorship have dedicated PA advocacy staff who can assist patients in navigating appeals. For inflammatory diseases, the Arthritis Foundation maintains advocacy resources specific to biologic access. These organizations know the payer landscape intimately and can apply pressure at channels individual practices can't access.

Referring your patient to the relevant advocacy organization isn't passing the buck — it's building a coordinated advocacy team.

Legislative Landscape: Change Is Happening

State-level PA reform has accelerated dramatically since 2022.

As of 2025, over 20 states have enacted PA reform legislation requiring timely turnaround standards, mandatory gold carding for qualifying physicians, and transparency requirements for denial criteria. Several states have banned step therapy override for certain drug categories. The Improving Seniors' Timely Access to Care Act established federal PA standards for Medicare Advantage that took effect in 2024.

Knowing the laws in your state matters. If a payer is violating a state-mandated turnaround requirement, you can report it to your state insurance commissioner. That's advocacy at the regulatory level, and it works.

The Honest Truth About Where This Leaves You

Advocacy through the PA process is exhausting work. It shouldn't fall entirely on individual clinicians and their already-stretched staff. The system is poorly designed, the administrative burden is disproportionate to any clinical benefit the approval process actually provides, and patients bear the consequences of delays they didn't cause and can't control.

All of that is true. And it doesn't change the reality that right now, today, your patient is waiting for an approval while their disease continues. The most powerful thing you can do for them is move that approval forward as fast as possible — with thorough documentation, active tracking, and willingness to engage the appeal and peer-to-peer process when the first submission doesn't succeed.

Advocacy isn't a feeling. It's a set of actions with measurable outcomes.

Sources:
American Medical Association. (2024). 2024 AMA Prior Authorization Physician Survey. ama-assn.org
Centers for Medicare & Medicaid Services. (2024). Medicare Appeals Process. cms.gov
National Coalition for Cancer Survivorship. (2024). Prior Authorization and Cancer Care. canceradvocacy.org
Arthritis Foundation. (2024). Prior Authorization Advocacy Resources. arthritis.org
U.S. Congress. (2023). Improving Seniors' Timely Access to Care Act (H.R. 3173). congress.gov